Nicolet Advisory Services LLC Acquires 443 Shares of Bio-Techne Co. (NASDAQ:TECH)

Nicolet Advisory Services LLC increased its holdings in shares of Bio-Techne Co. (NASDAQ:TECH) by 7.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,071 shares of the biotechnology company’s stock after purchasing an additional 443 shares during the period. Nicolet Advisory Services LLC’s holdings in Bio-Techne were worth $449,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its position in Bio-Techne by 92.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,746,119 shares of the biotechnology company’s stock valued at $404,470,000 after acquiring an additional 2,755,065 shares in the last quarter. Mackenzie Financial Corp boosted its position in Bio-Techne by 8.2% during the second quarter. Mackenzie Financial Corp now owns 2,862,260 shares of the biotechnology company’s stock valued at $205,081,000 after purchasing an additional 216,044 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Bio-Techne by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,589,799 shares of the biotechnology company’s stock valued at $185,559,000 after purchasing an additional 88,257 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Bio-Techne by 20.4% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,714,994 shares of the biotechnology company’s stock valued at $122,879,000 after buying an additional 290,510 shares during the last quarter. Finally, Geneva Capital Management LLC lifted its position in shares of Bio-Techne by 1.6% during the third quarter. Geneva Capital Management LLC now owns 1,104,310 shares of the biotechnology company’s stock valued at $88,267,000 after buying an additional 17,114 shares during the last quarter. 98.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TECH has been the subject of several recent analyst reports. Robert W. Baird boosted their price objective on shares of Bio-Techne from $82.00 to $84.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Scotiabank increased their price objective on Bio-Techne from $83.00 to $88.00 and gave the company a “sector outperform” rating in a report on Thursday, October 31st. Royal Bank of Canada dropped their target price on Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 8th. StockNews.com upgraded Bio-Techne from a “hold” rating to a “buy” rating in a research note on Tuesday, November 12th. Finally, Benchmark restated a “buy” rating and set a $95.00 price objective on shares of Bio-Techne in a report on Tuesday, August 13th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.78.

Bio-Techne Trading Up 0.3 %

Bio-Techne stock opened at $71.28 on Friday. The company has a current ratio of 4.56, a quick ratio of 3.26 and a debt-to-equity ratio of 0.14. The firm has a market cap of $11.33 billion, a PE ratio of 75.83, a P/E/G ratio of 5.19 and a beta of 1.28. The stock’s 50 day simple moving average is $73.77 and its two-hundred day simple moving average is $75.25. Bio-Techne Co. has a 12 month low of $61.16 and a 12 month high of $85.57.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.38 by $0.04. The company had revenue of $289.46 million for the quarter, compared to analyst estimates of $280.22 million. Bio-Techne had a net margin of 12.86% and a return on equity of 12.76%. The firm’s revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the business earned $0.35 earnings per share. Analysts anticipate that Bio-Techne Co. will post 1.68 earnings per share for the current year.

Bio-Techne Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, November 22nd. Investors of record on Monday, November 11th were paid a $0.08 dividend. The ex-dividend date of this dividend was Friday, November 8th. This represents a $0.32 annualized dividend and a dividend yield of 0.45%. Bio-Techne’s dividend payout ratio is presently 34.04%.

Bio-Techne Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.